iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin gets EIR from USFDA for Dabhasa facility

15 Jul 2024 , 03:03 PM

Lupin’s stock jumped in early trading on July 15 after the business got the United States Food and Drug Administration’s (USFDA) Establishment Inspection Report (EIR) for its Dabhasa, Gujarat manufacturing facility.

At around 2.44 PM, Lupin was trading 2.13% higher at Rs 1,836 per piece, against the previous close of Rs 1,797.75 on NSE. The counter touched an intraday high and low of Rs 1,839.05, and Rs 1,801.25, respectively.

The EIR was issued following the facility’s latest inspection, which took place from April 8 to April 12, 2024.

The inspection finished with no observations, and the facility was classified as “No Action Indicated” (NAI).

The plant is part of Lupin Manufacturing Solutions (LMS), a company that develops, manufactures, and sells active pharmaceutical ingredients, as well as conducts contract development and manufacturing.

Lupin’s recent success in the US (sales climbed ~34% YoY in FY24) is due to its improved regulatory track record and traction in the inhalation portfolio. Following the launch of gSpiriva, the share of inhalation products in US sales increased from 25% in FY22 (USD 185 million) to 40% in FY24 (USD 326 million).

Growth in India had been muted due to the cessation of in-licensed brands (contribution fell from 15% in FY23 to 11% in Q4FY24), according to the broking company.

 

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Lupin
  • Lupin News
  • Lupin Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

SBI Card Q4 Profit Slips 20%
25 Apr 2025|11:17 PM
HUL Q4 Net Profit Rises to ₹2,493 Crore
25 Apr 2025|10:59 PM
Sensex and Nifty in Red on April 25, 2025
25 Apr 2025|02:08 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.